The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease
Open accessAbstract
BACKGROUND: Alterations in blood-brain barrier permeability have been proposed to represent a relevant factor contributing to Parkinson's disease progression. However, few studies have addressed this issue in patients at different stages of disease. METHODS: Albumin was measured in cerebrospinal fluid and serum samples obtained from 73 non-demented subjects with idiopathic Parkinson's disease and 47 age-matched control subjects. The albumin ratio (AR) was calculated to assess blood-cerebrospinal fluid and blood-brain barrier function. The group of patients with Parkinson's disease included 46 subjects with Hoehn-Yahr staging between 1 and 2 and 27, with a score ranging from 2.5 to 4. RESULTS: Statistically significant differences in albumin ratio were found between patients with advanced disease, and both early-stage and unaffected groups. Conversely, early-phase patients did not differ from healthy subjects. Additionally, dopaminergic treatment seems to exert a possible effect on AR values. CONCLUSIONS: Our study demonstrates that possible dysfunction of the blood-cerebrospinal fluid barrier, blood-brain barrier, or both, characterize Parkinson's disease progression. The associations between clinical scores, treatments and biochemical findings suggest a progressive impairment of barrier integrity during the course of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These biomarkers are further altered as patients progress into more advanced PD stages with dementia (288, 474).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [474]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Merritt, H. H., FREMONT-SMITH, F., & Ayer, J. B. (1938) · The American Journal of the Medical Sciences · doi:10.1097/00000441-193804000-00024 · Cited by 880
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845
Self-citationBlood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
The Blood-Brain Barrier in Brain Homeostasis and Neurological Diseases
Weiss, N., Miller, F., Cazaubon, S., & Couraud, P.-O. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.10.022 · Cited by 731
Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood
Barbour, R., Kling, K., Anderson, J. P., Banducci, K., Cole, T. A., Diep, L., Fox, M., Goldstein, J. M., Soriano, F., Seubert, P. A., et al. (2008) · Neurodegenerative Diseases · doi:10.1159/000112832 · Cited by 548
Dynamics of brain-derived proteins in cerebrospinal fluid
Reiber, H. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00573-3 · Cited by 512
THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE
Gibb, W. R. G., & Lees, A. J. (1989) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1989.tb01147.x · Cited by 325
The natural history of treated Parkinson's disease in an incident, community based cohort
Evans, J., Mason, S., Williams‐Gray, C. H., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240366 · Cited by 235
Cited by
Sorted by citations
Items 101–158 of 158
Bruschi, G., Bortolin, E., Mazzeo, S., Bombaci, A., Pozzi, F. E., Agosta, F., Ferini‐Strambi, L., Filippi, M., & Salsone, M. (2025) · SLEEP · doi:10.1093/sleep/zsaf174 · Cited by 13
Fatty acid uptake in Trypanosoma brucei: Host resources and possible mechanisms
Poudyal, N. R., & Paul, K. S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.949409 · Cited by 16
Thiollier, T., Wu, C., Contamin, H., Li, Q., Zhang, J., & Bézard, E. (2016) · Synapse · doi:10.1002/syn.21889 · Cited by 13
Fang, X. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0239-x · Cited by 11
Gastrointestinal Dysfunction Bears on the Clinical‐Biological Profile of Parkinson's Disease
Bissacco, J., Bovenzi, R., Conti, M., Simonetta, C., Mascioli, D., Cerroni, R., Sancesario, G. M., Grillo, P., Pierantozzi, M., Stefani, A., et al. (2024) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.14319 · Cited by 10
Self-citationAlbumin: Bountiful Arrow in the Quiver of Liver and Its Significance in Physiology
Baral, A. (2025) · Livers · doi:10.3390/livers5020027 · Cited by 10
Albumin heterogeneity in low-abundance fluids. The case of urine and cerebro-spinal fluid
Bruschi, M., Santucci, L., Candiano, G., & Ghiggeri, G. M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.026 · Cited by 10
Yang, J., Lin, W., Ma, Y., Song, H., Mu, C., Wu, Q., Chen, H., Zhang, J., & Liu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1370831 · Cited by 9
Pathophysiology of the choroid plexus in brain diseases
Mihaljević, S., Michalicová, A., Bhide, M., & Kováč, A. (2021) · General Physiology and Biophysics · doi:10.4149/gpb_2021032 · Cited by 9
Wang, F., Ni, J., Wang, X., Xie, B., Feng, C., Zhao, S., Saeed, Y., Qing, H., & Deng, Y. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1547-8 · Cited by 9
Nakagawa, Y., & Yamada, S. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05153-3 · Cited by 8
Astrocytic S100B, Blood-Brain Barrier and Neurodegenerative Diseases
Krishnan, A., Wu, H., & Venkataraman, V. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92146 · Cited by 8
Immunological aspects of Parkinson's disease
Belova, O. V., Arefieva, T. I., & Moskvina, S. N. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2020120021110 · Cited by 8
Fang, J., Wang, X., Su, X., Li, D., Wang, F., Wang, P., Yuan, C., Ji, F., Zhang, D., Cai, X., et al. (2025) · The Innovation Life · doi:10.59717/j.xinn-life.2025.100164 · Cited by 7
Kronberger, J., Balber, T., Schueffl, H. H., Wahrmann, R., Federa, A., Gradl, M., Brandt, M., Wanek, T., Mitterhauser, M., Kowol, C. R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00803 · Cited by 6
Vandendriessche, C., Bruggeman, A., Foroozandeh, J., Hoecke, L. V., Dujardin, P., Xie, J., Imschoot, G. V., Wonterghem, E. V., Castelein, J., Lucci, C., et al. (2024) · eNeuro · doi:10.1523/eneuro.0024-23.2024 · Cited by 6
Stefani, A., Olivola, E., Bassi, M. S., Pisani, V., Imbriani, P., Pisani, A., & Pierantozzi, M. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312040016 · Cited by 6
Self-citationConti, M., Ferrari, V., Pierantozzi, M., Simonetta, C., Carparelli, F., D’Angelo, V., Bagetta, S., Giuliano, F. D., Mercuri, N. B., Schirinzi, T., et al. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03002-1 · Cited by 5
Self-citationZanardi, A., Barbariga, M., Conti, A., Vegliani, F., Curnis, F., & Alessio, M. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105474 · Cited by 6
Long Term Effect of COVID-19 on the Brain: Review
Devkumar, S., Jha, R. K., & Chandi, D. H. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i39b32173 · Cited by 5
Hefermehl, A. K., Hensen, S. M. M., Versantvoort, C., Rothermel, A., & Şahin, U. (2023) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2023.08.003 · Cited by 4
Lu, J., Wang, X., Xu, F., Rao, C., Guo, Y., Su, Z., Chen, S., & Li, Q. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1412434 · Cited by 4
Nano-carriers for brain disorders targeting the blood brain barrier (BBB) crossing strategies
Gupta, K. R., Dabhekar, S., Dixit, M., & Umekar, M. J. (2021) · Indian Journal of Pharmacy and Pharmacology · doi:10.18231/j.ijpp.2020.035 · Cited by 4
Clinical Aspects of Inflammation in Parkinson’s Disease
Thomas, M., & Adams, C. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_8 · Cited by 4
Garg, P., Würtz, F., Hobbie, F., Buttgereit, K., Aich, A., Leite, K., Rehling, P., Kügler, S., & Bähr, M. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03050-6 · Cited by 3
Investigating the Genetic Association of 40 Biochemical Indicators with Parkinson’s Disease
Wang, Z., Xia, H., Shi, J., Fan, P., Cao, Q., Ding, Y., Du, X., & Yang, X. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02273-9 · Cited by 3
Immunity in Parkinson's disease – The role of innate responses
Iyengar, A. S., Dunkley, P. R., & Dickson, P. W. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578716 · Cited by 4
Lu, Z., Yin, H., Xiang, P., Yi, X., Tian, X., & Gong, Q. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70237 · Cited by 4
Li, M., Gan, J., Yang, X., Liu, S., & Ji, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1390036 · Cited by 3
Shim, Y., Choi, S. A., Dan, K., Koh, E. J., Ha, S., Phi, J. H., Kim, J. W., Han, D., & Kim, S. (2025) · Translational Stroke Research · doi:10.1007/s12975-025-01384-8 · Cited by 2
Role of the Innate and Adaptive Immune System in the Pathogenesis of PD
Kannarkat, G. T., & Tansey, M. G. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_3 · Cited by 2
Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases
Olson, K. E., Mosley, R. L., & Gendelman, H. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_8 · Cited by 2
Taneva, S. G., Todinova, S. J., Danailova, A., Atanassov, K. T., & Atanassova, V. (2026) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-025-15269-3 · Cited by 1
The Role of Blood-Retinal Barrier in Retinal Neurodegenerative Diseases
Blankenborg, L., Anand‐Apte, B., & Biswas, S. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.05.002 · Cited by 1
Szukiewicz, D., Almeida‐de‐Souza, J., Gryka-Marton, M., Wątroba, M., & Grabowska, A. D. (2026) · Nutrients · doi:10.3390/nu18132106 · Cited by 1
Tian, J., Liu, X., Li, Y., Gu, Y., Deng, B., Yang, W., Yu, H., Zhang, X., & Chen, X. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120145 · Cited by 1
Stoll, A. C., & Harms, A. S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1765195 · Cited by 1
Gut, brain and the Glycocalyx: A portrait of Parkinsons disease
Ninham, B. W., Battye, M., & Carlin, M. R. (2026) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2026.103880 · Cited by 1
Yao, W., Liu, L., Wang, J., Chen, S., Zhang, C., Liao, R., Wang, Y., Ou, K., Jiang, L., Yu, Y., et al. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01738-2 · Cited by 1
Саидвалиев, Ф. С., Pulatova, D., Kilichev, I. A., Yusupov, A., Шамуратова, Г. Б., Turdibekov, X., Pulatov, M., Baxtiyorovich, S. J., Mirhayotova, N., Axmedova, Y., et al. (2026) · BMC Neurology · doi:10.1186/s12883-026-04963-w · Cited by 1
Brain penetration of benserazide inversely associates with levodopa response in Parkinson’s disease
Lu, S., Wu, L., Huang, Q., Chen, L., Li, M., & Ma, S. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01491-9 · Cited by 1
Is Chronic Systemic Inflammation a Determinant Factor in Developing Parkinson’s Disease?
Ugalde‐Muñiz, P., Pérez‐Hernández, J., & Chavarría, A. (2016) · InTech eBooks · doi:10.5772/62955 · Cited by 1
Ovallath, S., & Sulthana, B. (2018) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_4_18 · Cited by 1
Neuroinflammation: Peripheral and Neurogenic Underlying Processes
Rodriguez-Ramirez, J., Adalid-Peralta, L. V., Fragoso, G., Rosas, G., Meneses, G., Fleury, A., Sciutto, E., & Gardenas, G. (2015) · Journal of Contemporary Immunology · doi:10.7726/jci.2015.1002
Signaling Mechanisms in l-DOPA-Induced Dyskinesia
Alcacer, C., Francardo, V., & Cenci, M. A. (2016) · Innovations in cognitive neuroscience · doi:10.1007/978-3-319-42743-0_8
Local Treatment of Brain Tumors and the Blood-Brain Barrier
Rajsiglová, L., & Vannucci, L. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-75007-1_7
Blood–brain barrier targeted nanoparticles
Obulesu, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819882-7.00003-9
Immunoinflammatory Aspects of Parkinson’s Disease
Belova, O. V., Arefieva, T. I., & Moskvina, S. N. (2020) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-020-01014-w
Sharma, P., & Dhamija, R. K. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102113
Qiu, X., Hu, H., Bai, X., Wang, X., You, C., Ma, L., Tao, C., & Wen, D. (2025) · Neurosurgical Review · doi:10.1007/s10143-025-03801-w
Garg, P., Würtz, F., Hobbie, F., Buttgereit, K., Aich, A., Leite, K., Rehling, P., Kügler, S., & Bähr, M. (2024) · Figshare · doi:10.6084/m9.figshare.25310253
Garg, P., Würtz, F., Hobbie, F., Buttgereit, K., Aich, A., Leite, K., Rehling, P., Kügler, S., & Bähr, M. (2024) · Figshare · doi:10.6084/m9.figshare.25310136
Folke, J., DellaValle, B., Jørgensen, M. L., Mogensen, P. B., Hempel, C., Rungby, J., Hejl, A., Løkkegaard, A., Salvesen, L., Bech, S., et al. (2026) · Movement Disorders · doi:10.1002/mds.70274
Understanding the role of perivascular macrophages in Parkinson's disease pathophysiology
Fuentealba, J. R. (2017) · theses.fr (ABES) · doi:10.70675/b2e8f905z4f72z497eza017zc5b9d7fe53a1
Body Fluid-based Biomarkers for Cognitive Impairment in Parkinson’s Disease
Ragini, R., Choudhury, S., Krithika, N. C., Bharath, M. M. S., Rathod, B. L. S., Yadav, R., & Alladi, P. A. (2026) · Annals of Neurosciences · doi:10.1177/09727531261442666
Xiu, W., Zhang, G. N., Chen, Y., Sun, C., Gao, Y., Li, A., Zhang, H., Shuai, P., Deng, B., Cheng, J., et al. (2026) · European journal of medical research · doi:10.1186/s40001-026-04761-7
Metadata
- Authors
- Pisani, V., Stefani, A., Pierantozzi, M., Natoli, S., Stanzione, P., Franciotta, D., & Pisani, A.
- Affiliations
- University of Rome Tor Vergata (IT)
- Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
- Corresponding author
- Pisani, Antonio
- ORCID
- Venue
- Journal of Neuroinflammation
- Published
- 2012-08-08
- Volume
- 9
- Issue
- 1
- Pages
- 188-188
- ISSN
- 1742-2094 (ISSN-L)
- PMC
- PMC3441323
- OpenAlex
- W2155862034
- Cited by
- 158
- References
- 21
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 15 · 2023: 7 · 2022: 11 · 2021: 11 · 2020: 18 · 2019: 9 · 2018: 17 · 2017: 9 · 2016: 10 · 2015: 12 · 2014: 6 · 2013: 7 · 2012: 1
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Neuroinflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Istituto Nazionale per l'Assicurazione Contro Gli Infortuni sul Lavoro
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Parkinson's disease, blood-brain barrier permeability, blood-CSF barrier, albumin ratio, cerebrospinal fluid albumin, disease progression, Hoehn-Yahr staging, dopaminergic therapy, barrier dysfunction
- MeSH terms
- Adult, Aged, Aged, 80 and over, Albumins, Blood-Brain Barrier, Female, Humans, Male, Middle Aged, Parkinson Disease, Severity of Illness Index, Cohort Studies, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
